SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
Plexxikon Gets $15M Investment For Diabetes Drug Development (BioWorld Today)
News | 05. 27. 2004
Plexxikon
Plexxikon Inc. raised $15 million in venture financing to complete a Series B extension round.
